A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma.

Trial Profile

A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Pazopanib (Primary) ; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 01 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 05 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top